Literature DB >> 16685139

Outcome and treatment of bucillamine-induced nephropathy.

Junichi Hoshino1, Yoshifumi Ubara, Shigeo Hara, Tatsuya Suwabe, Naoki Sawa, Tetsuo Tagami, Hideyuki Katori, Fumi Takemoto, Shigeko Hara, Kenmei Takaichi.   

Abstract

BACKGROUND: Bucillamine (BCL), a treatment for rheumatoid arthritis, occasionally causes proteinuria. Renal specimens are reported to show segmental granular deposition of immunoglobulin G, associated with membranous nephropathy. Long-term course and optimal treatment have remained unknown, and were investigated here.
METHODS: We examined clinical records of 400 patients treated with BCL for rheumatoid arthritis, at our hospital from 1998 to 2003, finding 17 with proteinuria and biopsy-proven BCL-induced nephropathy.
RESULTS: In all 17 patients, proteinuria resolved without loss of renal function between 3 and 85 months after discontinuing BCL (14.1 +/- 3.4). The only factor influencing time to remission was pathologic stage of membranous nephropathy (stage I vs. stage II or III: 11.5 +/- 4.8 vs. 21.6 +/- 3.3 months; p = 0.02). Maximal proteinuria, total amount of BCL, BCL exposure time, and use of prednisolone or other immunosuppressant agents did not significantly influence time until remission.
CONCLUSION: The most important therapeutic step in treating BCL-induced nephropathy is to discontinue BCL. Prednisolone or other immunosuppressant agents might not be effective. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16685139     DOI: 10.1159/000093254

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  4 in total

1.  Comparative proteomic analysis of glomerular proteins in primary and bucillamine-induced membranous nephropathy.

Authors:  Hajime Kaga; Hirotoshi Matsumura; Takehiro Suzuki; Naoshi Dohmae; Masafumi Odaka; Atsushi Komatsuda; Naoto Takahashi; Hideki Wakui
Journal:  Clin Proteomics       Date:  2022-07-14       Impact factor: 5.000

2.  Bucillamine-induced membranous nephropathy with crescent formation in a patient with rheumatoid arthritis: case report and literature review.

Authors:  Shun Manabe; Mayuko Banno; Marie Nakano; Teruhiro Fujii; Michio Fujiwara; Yasuhiko Kita; Kosaku Nitta; Michiyasu Hatano
Journal:  Case Rep Nephrol Dial       Date:  2014-10-29

3.  Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis: a retrospective analysis.

Authors:  Masato Sawamura; Naoki Sawa; Masayuki Yamanouchi; Daisuke Ikuma; Akinari Sekine; Hiroki Mizuno; Masahiro Kawada; Rikako Hiramatsu; Noriko Hayami; Eiko Hasegawa; Tatsuya Suwabe; Junichi Hoshino; Kei Kono; Keiichi Kinowaki; Kenichi Ohashi; Yutaka Yamaguchi; Yoshifumi Ubara
Journal:  Clin Exp Nephrol       Date:  2021-11-30       Impact factor: 2.801

4.  HLA-DRB1*08:02 Is Associated with Bucillamine-Induced Proteinuria in Japanese Rheumatoid Arthritis Patients.

Authors:  Hiroshi Furukawa; Shomi Oka; Kota Shimada; Shoji Sugii; Atsushi Hashimoto; Akiko Komiya; Naoshi Fukui; Taiichiro Miyashita; Kiyoshi Migita; Akiko Suda; Shouhei Nagaoka; Naoyuki Tsuchiya; Shigeto Tohma
Journal:  Biomark Insights       Date:  2014-05-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.